It’s a sign that’s impossible to ignore. As you soon as you pull up the Price Overview for Recursion Pharmaceuticals (RXRX), you’re greeted with a clear message: Barchart’s Technical Opinion indicator rates RXRX stock as a 72% Strong Sell. From an empirical perspective, suggesting a contrarian position would place you on shaky ground.
Since the start of the year, RXRX stock is down nearly 28%, which in many respects is understandable given the uncertainties associated with the broader healthcare ecosystem. A clinical-stage biotechnology firm, Recursion focuses on innovations tied to biology, chemistry, automation, data science and engineering. However, with question marks surrounding drug pricing and other matters, even major pharmaceuticals like Eli Lilly (LLY) and Pfizer (PFE) have failed to deliver the goods for shareholders this year.
